Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status

NCT00813943 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

265

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Cilengitide (2-times weekly)
DRUG: cilengitide (5-times weekly)
DRUG: Temozolomide
RADIATION: Radiotherapy

Sponsor

EMD Serono

Collaborators

[object Object]